Real-World Efficacy of Ritlecitinib in Adolescent Patients With Alopecia Areata: A 36 Week Monocentric Real-Life Observational Study

医学 观察研究 药物警戒 安全概况 儿科 不利影响 临床试验 皮肤病科 梅德林 随机对照试验 年轻人 多中心研究 内科学 重症监护医学 患者安全
作者
Jundong Huang,Zhuoer Zhang,Jui-Jiun Jian,Min Li,Ruxin Ji,Tian Tian,Xiaobing Liang,Zhixiang Zhao,Yan Tang,Ji Li,Fangfen Liu,Wei Shi
出处
期刊:Journal of Cutaneous Medicine and Surgery [SAGE Publishing]
卷期号:30 (4): 369-373 被引量:3
标识
DOI:10.1177/12034754261429965
摘要

BACKGROUND: Ritlecitinib represents the sole therapeutic agent currently approved for adolescents aged 12 to 17 years with severe alopecia areata (AA). Despite its regulatory endorsement, real-world data characterizing treatment outcomes and tolerability profiles in pediatric populations remain conspicuously absent. OBJECTIVE: To systematically assess clinical response trajectories and treatment-emergent adverse events among adolescent AA patients treated with ritlecitinib in a real-world clinical cohort. METHODS: We conducted a retrospective review of electronic medical records from December 2023 to May 2025, including AA patients aged 12 to 17 years treated with ritlecitinib. Data collected included demographics, AA severity scores [Severity of Alopecia Tool (SALT)], Eyebrow Assessment, Eyelash Assessment, and safety outcomes. RESULTS: The study enrolled 30 patients aged 12 to 17 years, with a median baseline SALT score of 61.3 (interquartile range 40.5-88.25). Treatment was administered over a 36 week period. By week 36, clinically meaningful improvements in SALT scores were observed: 96.7% of patients achieved at least a 30% reduction, while 86.7% and 70.0% attained reductions of ≥50% and ≥80%, respectively. At this time point, 24 patients (80.0%) achieved SALT scores ≤20. Among patients with baseline eyebrow or eyelash involvement, sustained regrowth was observed throughout the treatment period. All 6 patients with eyebrow involvement and all 5 with eyelash involvement exhibited complete recovery. Adverse events were predominantly mild, with folliculitis representing the most frequently reported event (n = 7). LIMITATIONS: Single-center, retrospective design. CONCLUSIONS: Real-world utilization of ritlecitinib demonstrated robust efficacy in AA while maintaining a favorable safety profile among adolescent populations, with no novel safety signals identified beyond established pharmacovigilance parameters.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丰富的绮波完成签到 ,获得积分10
刚刚
Kuzu完成签到,获得积分10
刚刚
cjh发布了新的文献求助10
1秒前
哭嘻嘻关注了科研通微信公众号
1秒前
苹果大福完成签到,获得积分10
1秒前
小李发布了新的文献求助10
2秒前
dongdongdong完成签到,获得积分10
2秒前
弓长完成签到 ,获得积分10
3秒前
3秒前
3秒前
4秒前
zzz完成签到,获得积分10
4秒前
豆浆关注了科研通微信公众号
5秒前
6秒前
骤世界完成签到 ,获得积分10
7秒前
机智的水饺完成签到,获得积分10
7秒前
7秒前
Jun的应助被xh采纳,获得10
7秒前
8秒前
Nole的应助被里大炮采纳,获得10
8秒前
chencc发布了新的文献求助10
8秒前
在水一方的应助被科研小白采纳,获得30
9秒前
10秒前
10秒前
11秒前
lx发布了新的文献求助10
11秒前
搜集达人的应助被老实人采纳,获得10
11秒前
12秒前
mimilv发布了新的文献求助10
13秒前
zero发布了新的文献求助10
13秒前
科目三的应助被lbh采纳,获得10
13秒前
可爱的函函的应助被小李采纳,获得10
14秒前
15秒前
kszzcy发布了新的文献求助10
15秒前
16秒前
16秒前
阔达的心情完成签到,获得积分10
16秒前
16秒前
哭嘻嘻发布了新的文献求助10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191571
求助须知:如何正确求助?哪些是违规求助? 9578332
关于积分的说明 21858634
捐赠科研通 7790907
什么是DOI,文献DOI怎么找? 3436656
关于科研通互助平台的介绍 2560375
邀请新用户注册赠送积分活动 2483446